Pharmaceutics (Aug 2022)

The Role of Polymeric Biomaterials in the Treatment of Articular Osteoarthritis

  • Carmen Velasco-Salgado,
  • Gloria María Pontes-Quero,
  • Luis García-Fernández,
  • María Rosa Aguilar,
  • Kyra de Wit,
  • Blanca Vázquez-Lasa,
  • Luis Rojo,
  • Cristina Abradelo

DOI
https://doi.org/10.3390/pharmaceutics14081644
Journal volume & issue
Vol. 14, no. 8
p. 1644

Abstract

Read online

Osteoarthritis is a high-prevalence joint disease characterized by the degradation of cartilage, subchondral bone thickening, and synovitis. Due to the inability of cartilage to self-repair, regenerative medicine strategies have become highly relevant in the management of osteoarthritis. Despite the great advances in medical and pharmaceutical sciences, current therapies stay unfulfilled, due to the inability of cartilage to repair itself. Additionally, the multifactorial etiology of the disease, including endogenous genetic dysfunctions and exogenous factors in many cases, also limits the formation of new cartilage extracellular matrix or impairs the regular recruiting of chondroprogenitor cells. Hence, current strategies for osteoarthritis management involve not only analgesics, anti-inflammatory drugs, and/or viscosupplementation but also polymeric biomaterials that are able to drive native cells to heal and repair the damaged cartilage. This review updates the most relevant research on osteoarthritis management that employs polymeric biomaterials capable of restoring the viscoelastic properties of cartilage, reducing the symptomatology, and favoring adequate cartilage regeneration properties.

Keywords